FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O. Burst Edition: FDA approvals of Imjudo (tremelimumab) in combination with durvalumab for unresectable hepatocellular carcinoma, and Tecvayli (teclistamab-cqyv) for relapsed or refractory multiple myeloma

Listen Later
Listen to a soundcast of the October 21st and 25th 2022, FDA approvals of Imjudo (tremelimumab) in combination with durvalumab for unresectable hepatocellular carcinoma, and Tecvayli (teclistamab-cqyv) for relapsed or refractory multiple myeloma.
...more
View all episodesView all episodes
Download on the App Store
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)By U.S. Food and Drug Administration, Center for Drug Evaluation and Research
  • 4.4
  • 4.4
  • 4.4
  • 4.4
  • 4.4

4.4

14 ratings